Grace Therapeutics Valuation
| GRCE Stock | 3.60 0.12 3.45% |
At this time, the firm appears to be overvalued. Grace Therapeutics retains a regular Real Value of USD2.95 per share. The prevalent price of the firm is USD3.6. Our model calculates the value of Grace Therapeutics from evaluating the firm fundamentals such as return on equity of -0.13, and Return On Asset of -0.12 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Grace Therapeutics' valuation include:
Overvalued
Today
Please note that Grace Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Grace Therapeutics is based on 3 months time horizon. Increasing Grace Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Grace stock is determined by what a typical buyer is willing to pay for full or partial control of Grace Therapeutics. Since Grace Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Grace Stock. However, Grace Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.6 | Real 2.95 | Target 12.05 | Hype 3.6 | Naive 3.53 |
The real value of Grace Stock, also known as its intrinsic value, is the underlying worth of Grace Therapeutics Company, which is reflected in its stock price. It is based on Grace Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Grace Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Grace Therapeutics helps investors to forecast how Grace stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Grace Therapeutics more accurately as focusing exclusively on Grace Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Grace Therapeutics' intrinsic value based on its ongoing forecasts of Grace Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Grace Therapeutics' closest peers. If more than one evaluation category is relevant for Grace Therapeutics we suggest using both methods to arrive at a better estimate.
Grace Therapeutics Cash |
|
Grace Therapeutics Total Value Analysis
Grace Therapeutics is currently forecasted to have valuation of 32.93 M with market capitalization of 54.63 M, debt of 5.38 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Grace Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
32.93 M | 54.63 M | 5.38 M |
Grace Therapeutics Asset Utilization
One of the ways to look at asset utilization of Grace is to check how much profit was generated for every dollar of assets it reports. Grace Therapeutics retains a negative application of resources of -0.12 (percent), losing USD0.001185 for each dollar of resources held by the firm. Unsuccessful asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Grace Therapeutics shows how unproductive it operates for each dollar spent on its resources.Grace Therapeutics Profitability Analysis
Based on Grace Therapeutics' profitability indicators, Grace Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Grace Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2008-09-30 | Previous Quarter -3.4 M | Current Value -938 K | Quarterly Volatility 5.6 M |
For Grace Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Grace Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Grace Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Grace Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Grace Therapeutics over time as well as its relative position and ranking within its peers.
Grace Therapeutics Earnings per Share Projection vs Actual
By analyzing Grace Therapeutics' earnings estimates, investors can diagnose different trends across Grace Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Grace Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Grace Therapeutics Ownership Allocation
The market capitalization of Grace Therapeutics is USD54.63 Million. Grace Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Grace Therapeutics Profitability Analysis
Net Loss for the year was (9.57 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Grace Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Grace Therapeutics and how it compares across the competition.
About Grace Therapeutics Valuation
The stock valuation mechanism determines Grace Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Grace Therapeutics. We calculate exposure to Grace Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Grace Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -6.3 K | -6 K | |
| Pretax Profit Margin | (90.36) | (94.88) | |
| Operating Profit Margin | (75.39) | (79.16) | |
| Net Loss | (90.36) | (94.88) | |
| Gross Profit Margin | 0.70 | 0.74 |
Grace Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Grace Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Grace we look at many different elements of the entity such as Grace's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Grace Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Grace Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Grace Therapeutics' worth.Complementary Tools for Grace Stock analysis
When running Grace Therapeutics' price analysis, check to measure Grace Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grace Therapeutics is operating at the current time. Most of Grace Therapeutics' value examination focuses on studying past and present price action to predict the probability of Grace Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grace Therapeutics' price. Additionally, you may evaluate how the addition of Grace Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |